The global pharmaceutical excipients market is projected to witness a CAGR of 7.31% during the forecast period to reach a total market size of $9.776B by 2026, increasing from $5.966B in 2019.
Excipients are pharmacologically inactive chemicals that are added to the active drug substance to help with lubricity, flowability, disintegration, taste, and may provide some type of antibacterial action, as well as helping physiological absorption of the medication. Some of the excipients used in pharmaceutical industries include fillers, binders, lubricants, flavoring agents, sweeteners, chelating agents, solvents, co-solvents, etc.
Tablets, capsules, oral liquids, topical creams and gels, implants, eye products, injectable products, inhalers, transdermal patches, and suppositories are a few of the dose forms available. Pharmaceutical excipients are used in pharmaceutical dosage forms to help the production process, protect, support, or increase stability.
Cancer, chronic lung disease, stroke, diabetes, and other chronic illnesses are today's leading causes of mortality and disability. In the United States alone, six out of ten individuals suffer from a chronic illness, needing frequent medication. According to the International Diabetes Federation (IDF), around 463 million individuals (20-79 years) had diabetes in 2019, with this number expected to climb to 700 million by 2045. Indicating a high demand for medication and thus Pharmaceutical Excipients.
R&D in pharmaceutical excipients has increased in the past few years. R&D is crucial in pharmaceutical excipients to enhance the production process and product quality, more research, and development is being done in pharmaceutical formulations using multi-functional excipients. Further, with the development of countries like China and India, R&D is expected to increase in the field of pharmaceutical excipients.
With increasing chronic diseases, the growing generics market leads to an increase in the development of excipients is the major factor driving the market growth. With the advancement of drug development, there is an increase in pharmaceutical excipients.
Pharmaceutical Excipients require mandatory inspections by the regulatory authorities of the manufacturing site. Further huge investment in R&D is a key drawback. If a new drug approval fails, the excipient also fails–even if it is not related to the excipient. Moreover, A huge amount of time and cost goes into creating an excipient.